Cargando…

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis

PURPOSE: The aim of this study was to analyze clinical characteristics of skeletal metastasis in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) and treatment outcomes of continued EGFR tyrosine kinase inhibitor (TKI) therapy in patients presenting with skeletal met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Sook-Hee, Kim, Yeon-Sil, Lee, Ji Eun, Kim, In-ho, Kim, Seung Joon, Han, Daehee, Yoo, Ie Ryung, Chung, Yang-Guk, Kim, Young-Hoon, Lee, Kyo-Young, Kang, Jin-Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946371/ https://www.ncbi.nlm.nih.gov/pubmed/26790969 http://dx.doi.org/10.4143/crt.2015.289

Ejemplares similares

Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer
por: Lee, Dong Soo, et al.
Publicado: (2015)

Radiation nephritis: (99m)Tc hydroxydiphosphonate bone scan, (99m)Tc dimercaptosuccinic acid renal scan, and (18)F-FDG PET/CT findings
por: Park, Hye Lim, et al.
Publicado: (2018)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
por: Ko, Yoon Ho, et al.
Publicado: (2007)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer
por: Chung, Mi Joo, et al.
Publicado: (2016)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

Serum Carcinoembryonic Antigen Levels and the Risk of Whole-body Metastatic Potential in Advanced Non-small Cell Lung Cancer
por: Lee, Dong Soo, et al.
Publicado: (2014)

Interstitial Lung Change in Pre-radiation Therapy Computed Tomography Is a Risk Factor for Severe Radiation Pneumonitis
por: Lee, Yun Hee, et al.
Publicado: (2015)

Correlation of histological components with tumor invasion in pulmonary adenocarcinoma
por: Moon, Youngkyu, et al.
Publicado: (2014)

YAC tripeptide of epidermal growth factor promotes the proliferation of HaCaT keratinocytes through activation of EGFR
por: Yoo, Yeon Ho, et al.
Publicado: (2014)

Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy
por: Lee, Hee Yeon, et al.
Publicado: (2019)

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
por: Kim, Tae-Jung, et al.
Publicado: (2017)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy
por: Choi, Kyu Hye, et al.
Publicado: (2021)

Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer
por: Hong, Kyung Sook, et al.
Publicado: (2018)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
por: Lee, Dong Soo, et al.
Publicado: (2013)

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients
por: Oh, Bo-Young, et al.
Publicado: (2011)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
por: Lee, Dong-Soo, et al.
Publicado: (2011)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer
por: Kwak, Yoo-Kang, et al.
Publicado: (2020)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Treatment outcome of maxillary sinus cancer
por: Won, Hye Sung, et al.
Publicado: (2009)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
por: Lee, Dong Soo, et al.
Publicado: (2012)

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Goag, Eun Kyong, et al.
Publicado: (2018)

Clinical Characteristics of False-Positive Lymph Node on Chest CT or PET-CT Confirmed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Lung Cancer
por: Lee, Jongmin, et al.
Publicado: (2018)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
por: Hong, Sook-hee, et al.
Publicado: (2022)

Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT
por: Park, Hye Lim, et al.
Publicado: (2016)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer
por: Kim, Giwon, et al.
Publicado: (2011)

Soft Tissue Necrosis in Head and Neck Cancer Patients After Transoral Robotic Surgery or Wide Excision With Primary Closure Followed by Radiation Therapy
por: Yun Hee, Lee, et al.
Publicado: (2016)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_fp9avgunbb8idinagdhafa4mb7